" class="no-js "lang="en-US"> D'Andre Carpenter - Medtech Alert
Monday, September 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
D'Andre Carpenter

D’Andre Carpenter

About D’Andre Carpenter

Dr. D’Andre Carpenter has a doctorate diploma as a nurse practitioner not too long ago served because the senior vice chairman and affiliate chief nurse government at Jefferson Well being/Thomas Jefferson College in Philadelphia, Pennsylvania’s largest tutorial medical heart, an $8 billion, 18 hospital built-in supply well being community.

Related Story

Appointments

 UnityPoint Health Announces New Chief Nursing Officer | Pharmtech Focus

UnityPoint Health Announces New Chief Nursing Officer

March 25 2022

UnityPoint Health® is pleased to announce that Dr. D’Andre Carpenter has been selected as Chief […]